Nexavar compulsory licence 'unjustified' says Biocon head; moots innovation fee
This article was originally published in Scrip
Executive Summary
Biocon's chairperson and managing director, Kiran Mazumdar-Shaw, believes that India may have erred in granting a compulsory licence for Bayer's anticancer Nexavar (sorafenib tosylate) and suggests that, in general, such licensing must entail an element of a one-time "innovation fee", payable to the innovator by the applicant.